Omega-3s & Longevity Biomarkers: Unlocking Healthspan by 2026

Omega-3 fatty acids, EPA and DHA, are under intense scrutiny for their role in healthspan. We analyse their impact on crucial longevity biomarkers.

# Omega-3s & Longevity Biomarkers: Unlocking Healthspan by 2026

Omega-3 fatty acids, principally eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have long been lauded for their broad health benefits, from cardiovascular protection to cognitive function. However, as the focus of longevity science shifts towards quantifying biological age and mitigating the hallmarks of ageing, it's pertinent to examine their impact on specific, measurable longevity biomarkers. Can Omega-3 supplementation genuinely modify biological age, dampen systemic inflammation, or maintain telomere integrity? This investigation aims to dissect the evidence, separating robust findings from aspirational claims, as we look towards 2026 and beyond.

Omega-3s are essential polyunsaturated fatty acids (PUFAs) that the human body cannot synthesise efficiently, thus requiring dietary intake. Found abundantly in fatty fish, these compounds are incorporated into cell membrane phospholipids, influencing fluidity, receptor function, and signalling pathways. Crucially, they serve as precursors to specialised pro-resolving mediators (SPMs) such as resolvins and protectins, which actively terminate inflammatory responses rather than simply blocking them. This mechanism is thought to underpin many of their benefits, making them a cornerstone for anyone looking to optimise their healthspan foundation. The question for us at Longevity Stack isn't just *if* they're beneficial, but *how* specifically they interact with the molecular signatures of ageing.

The Anti-Inflammatory Axis: hsCRP and IL-6

Chronic low-grade inflammation is a pervasive driver of age-related diseases. Biomarkers such as high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) are widely accepted indicators of systemic inflammation. Numerous studies have investigated the effect of Omega-3 supplementation on these markers.

*Evidence Quality:* Grade A for hsCRP; Grade B for IL-6.

A meta-analysis of randomised controlled trials (RCTs) published in *Atherosclerosis* involving over 2,000 participants consistently demonstrated that Omega-3 supplementation, particularly at higher doses (≥2g EPA+DHA daily), significantly reduces hsCRP levels. The effect size, while modest, is clinically meaningful, often translating to a 10-15% reduction in individuals with elevated baseline levels. This is often observed within 8-12 weeks of consistent intake. For IL-6, the evidence is less consistent. While some trials show a reduction, particularly in populations with pre-existing inflammatory conditions or metabolic syndrome, others report no significant change. This discrepancy might be due to varying dosages, participant populations, and the complex nature of IL-6 regulation. Our editorial take is that while Omega-3 (EPA/DHA) supplementation offers a reliable strategy for attenuating hsCRP, its impact on IL-6 requires further nuanced investigation, especially in apparently healthy populations. This anti-inflammatory action is a key component of Mitochondrial Optimization, as chronic inflammation can directly impair mitochondrial function.

Telomere Length: A Marker of Cellular Ageing

Telomeres, the protective caps at the ends of chromosomes, shorten with each cell division, eventually leading to cellular senescence. Telomere shortening is considered a hallmark of biological ageing. The hypothesis is that by reducing oxidative stress and inflammation, Omega-3s might help preserve telomere length.

*Evidence Quality:* Grade C.

Research on Omega-3s and telomere length is intriguing but far from conclusive. A 2010 study in *JAMA* involving individuals with coronary heart disease found that higher Omega-3 intake was associated with slower rates of telomere shortening over a five-year period (pubmed.ncbi.nlm.nih.gov/20085953/). However, subsequent RCTs designed to directly assess this relationship have yielded mixed results. Some studies report a beneficial effect, particularly with higher EPA concentrations, while others show no significant impact. The challenge lies in the multifactorial nature of telomere maintenance, which is influenced by genetics, lifestyle, stress, and a myriad of other factors. The variability in measurement techniques and study designs also contributes to the inconsistency. As of 2026, while the anti-inflammatory properties of Omega-3s *could* theoretically contribute to telomere preservation, the direct causal evidence from robust clinical trials remains weak. It’s an area of active research, but not a primary, evidence-backed benefit at present. This is a classic example where mainstream rhetoric often outpaces solid data.

Epigenetic Ageing and DNA Methylation Clocks

Epigenetic clocks, such as Horvath, GrimAge, and DunedinPACE, are currently considered the most accurate molecular estimators of biological age. These clocks measure patterns of DNA methylation across the genome. Can Omega-3s influence these complex epigenetic marks?

*Evidence Quality:* Grade C.

This is a nascent but exciting area of research. Preliminary *in vitro* and animal studies suggest that Omega-3s can modulate DNA methylation, impacting gene expression related to inflammation, metabolism, and lipid homeostasis. However, human interventional trials specifically investigating the impact of Omega-3 supplementation on epigenetic age acceleration are scarce. A handful of observational studies have reported associations between higher Omega-3 Index (a measure of EPA+DHA in red blood cell membranes) and a younger epigenetic age. For instance, a study in *Nature Communications* explored the link between dietary fatty acids and epigenetic ageing, suggesting potential associations, though causality cannot be inferred from such designs (nature.com/articles/s41467-020-19262-6). The mechanisms could involve alterations in one-carbon metabolism, direct effects on DNA methyltransferases, or indirect effects via inflammation reduction. As of early 2026, while the concept is biologically plausible, concrete, well-powered RCTs demonstrating a significant deceleration of epigenetic clocks by Omega-3 supplementation are largely absent. This area requires considerably more research before definitive conclusions can be drawn for widespread application in, say, executive performance protocols.

Apolipoprotein B (ApoB): A Critical Cardiovascular Marker

Apolipoprotein B (ApoB) is a protein that is a primary component of 'bad' cholesterol particles like LDL, VLDL, and Lp(a). High ApoB levels are a strong predictor of cardiovascular disease risk, often considered a more accurate marker than LDL-C alone. Reducing ApoB is a key strategy in mitigating cardiovascular risk, making it a relevant biomarker for healthspan.

*Evidence Quality:* Grade A.

Omega-3 fatty acids, particularly high-dose EPA (as seen in some prescription formulations), have a well-established effect on triglyceride reduction and, to a lesser extent, on ApoB. Clinical trials consistently show that EPA-rich Omega-3s can significantly lower triglyceride levels, which often correlates with a reduction in triglyceride-rich lipoprotein (TRL) remnants, and consequently, ApoB. While the effect on LDL-C can be variable (sometimes even increasing it in some individuals, particularly with DHA), the overall impact on ApoB is generally favourable, especially in hypertriglyceridemic patients. A notable study, the REDUCE-IT trial, demonstrated that icosapent ethyl (a prescription-grade EPA) significantly reduced cardiovascular events, with a concomitant reduction in ApoB. For individuals aiming for robust glucose control and improved lipid profiles, monitoring ApoB alongside traditional lipid panels is increasingly important, and Omega-3s can play a helpful role. This makes Omega-3s an important consideration for muscle preservation 50+ protocols where cardiovascular health is paramount.

NAD+ Levels: Energy and Repair

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme critical for numerous cellular processes, including energy metabolism, DNA repair, and sirtuin activity. NAD+ levels decline with age, and boosting them is a major focus in longevity research. Does Omega-3 supplementation influence NAD+?

*Evidence Quality:* Grade D.

There is virtually no direct evidence from human studies demonstrating that Omega-3 supplementation significantly impacts systemic NAD+ levels. While both Omega-3s and NAD+ are involved in metabolic regulation, their mechanistic pathways are distinct. Omega-3s primarily exert their effects through membrane modulation, inflammation resolution, and gene expression changes related to lipid metabolism. NAD+ precursors like NMN or NR directly feed into the NAD+ salvage pathways. While it's plausible there could be indirect, downstream interactions given the sheer complexity of cellular metabolism, attributing a direct NAD+-boosting effect to Omega-3s would be purely speculative at this point. In the context of longevity biomarkers, NAD+ is independently addressed by other interventions, making Omega-3s an unlikely candidate for this specific target. For interventions specifically targeting NAD+, one would look more towards compounds like NMN.

Benefits, Risks, and Contraindications

### Benefits (Biomarker-Specific)

* **Reduced hsCRP:** A consistent and well-evidenced benefit, crucial for mitigating systemic inflammation. * **Lower ApoB:** Significant reductions in those with elevated triglycerides, contributing to cardiovascular risk reduction. * **Potential Telomere Preservation:** Early evidence, but not yet robust enough for a primary claim. * **Limited Impact on Epigenetic Ageing and NAD+:** Currently, direct evidence is weak or non-existent.

### Risks

Omega-3 supplementation is generally well-tolerated. The most common side effects include gastrointestinal upset (burping, nausea, diarrhoea), which can often be mitigated by taking them with food or choosing enteric-coated formulations. High doses (above 3g/day of EPA+DHA) may increase the risk of bleeding, particularly if combined with anticoagulant medications. There's also a theoretical concern about increased LDL-C in some hypertriglyceridemic individuals receiving high DHA doses, though overall cardiovascular benefit usually outweighs this.

### Contraindications

Individuals on blood thinners like warfarin or clopidogrel should consult their GP before taking high-dose Omega-3s due to the increased bleeding risk. Those with fish or shellfish allergies should avoid fish oil supplements and opt for algal-based DHA. Pregnant or breastfeeding women should discuss appropriate dosages with their healthcare provider. Always remember, supplements are not a substitute for a balanced diet and professional medical advice [/legal/disclaimer].

The Bottom Line in 2026

For those targeting specific longevity biomarkers, high-quality Omega-3 (EPA/DHA) supplementation remains a **worthwhile intervention for significantly reducing hsCRP and improving ApoB levels**, particularly in individuals with higher baseline cardiovascular risk factors. The evidence for these benefits is strong (Grade A), making it a foundational supplement for many healthy ageing strategies. However, if your primary goal is to directly reverse epigenetic age, extend telomeres, or boost NAD+ levels, Omega-3s are **not the primary solution** in 2026. While biologically plausible, robust human data for these outcomes is either weak or non-existent (Grade C or D). Divert your resources to interventions with stronger evidence for those specific goals. Always consider your individual biomarker profile and consult with a healthcare professional to tailor your supplement regimen. We've seen first-hand at Longevity Stack that a targeted approach, grounded in evidence, yields the most impactful results for healthspan.